ETA2022 Poster Presentations Thyroid Cancer Diagnosis & Treatment (9 abstracts)
Clinical relevance of lower titer thyroglobulin (TG) autoantibodies in patients with differentiated thyroid carcinoma
Bernadette Dekker 1 , Anouk van der Horst-Schrivers 2 , A.H. Brouwers 3 , Chris Shuford 4 , Ido Kema 5 , Anneke Muller Kobold 6 & Thera Links 7
1University of Groningen, University Medical Center Groningen, Internal Medicine, Department of Endocrinology, Groningen, the Netherlands., Endocrinology, Groningen, Netherlands; 2University of Groningen, University Medical Center Groningen, Internal Medicine, Department of Endocrinology, Groningen, the Netherlands, Netherlands; 3University Medical Center Groningen, University of Groningen, University Medical Center Groningen, Department of Nuclear Medicine and Molecular Imaging Groningen, Groningen, Netherlands; 4Laboratory Corporation of America Holdings, Center for Esoteric Testing, Burlington, Nc, United States, United States; 5University of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, the Netherlands, Netherlands; 6University Medical Center Groningen, University of Groningen, University Medical Center Groningen, Department of Laboratory Medicine, Groningen, the Netherlands.*, Department of Laboratory Medicine, Groningen, Netherlands; 7University Medical Center Groningen, Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Department of Endocrinology, Groningen, Netherlands
Objectives: Thyroglobulin (Tg) is an established tumor marker for differentiated thyroid carcinoma (DTC) patients. However, Tg immunoassays can be subject to autoantibody (TgAb) interference resulting in incorrect Tg values. Tg measurement with liquid chromatography-tandem mass spectrometry (LC-MS/MS) could be promising in patients with TgAbs. In this study, we compared a Tg immunoradiometric assay (Tg-IRMA) and a Tg-LC-MS/MS analytically in the presence of TgAbs. Furthermore, we evaluated the clinical concordance between both assays in DTC patients with lower TgAbs titers (<10 U/ml) TgAbs during 131I ablation therapy.
Methods: 118 DTC patients diagnosed between 2006 and 2014 in a University Medical Center were followed up with the Tg-IRMA (Thermo Fischer Scientific) and ARCHITECT Anti-Tg (Abbott Laboratories) assays. TgAbs ≥ 10 U/ml were defined as potentially interfering. We re-analyzed their samples with a sensitive Tg-LC-MS/MS method (Labcorp, North Carolina, USA, limit of quantification of 0.02 ng/ml). Passing-Bablok regression analysis was performed on samples obtained during 131I ablation therapy and follow-up.
Results: In 304 samples with lower titer TgAb titers, good agreement was found between both Tg assays (slope of 1.09 (95% CI 1.05 - 1.16)). Fifty-five samples with potentially interfering TgAbs showed higher Tg-LC-MS/MS values than Tg-IRMA (slope of 1.45 (95% CI 1.12->>100)). For patients (n = 91) with lower TgAb titers at the time of 131I ablation therapy, the clinical concordance of both Tg assays was 91.2%.
Conclusions: In DTC patients with lower titer TgAbs, Tg-IRMA is a reliable and useful tumor marker. In DTC patients with potentially interfering TgAbs, Tg-IRMA values are decreased due to TgAb interference.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more